tradingkey.logo

Insulet Corp

PODD
311.950USD
-4.220-1.33%
Close 10/30, 16:00ETQuotes delayed by 15 min
21.96BMarket Cap
93.00P/E TTM

Insulet Corp

311.950
-4.220-1.33%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Insulet Corp

Currency: USD Updated: 2025-10-30

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Insulet Corp's Score

Industry at a Glance

Industry Ranking
36 / 210
Overall Ranking
106 / 4621
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 27 analysts
Buy
Current Rating
360.556
Target Price
+14.04%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Insulet Corp Highlights

StrengthsRisks
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, the Omnipod Insulin Management System, and Omnipod GO. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen's Neulasta. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. Omnipod 5 includes an AID algorithm embedded in the Pod.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 58.71% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.07B.
Fairly Valued
The company’s latest PE is 92.76, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 71.86M shares, decreasing 4.80% quarter-over-quarter.
Held by Baillie Gifford
Star Investor Baillie Gifford holds 2.14M shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-30

The company's current financial score is 9.35, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 649.10M, representing a year-over-year increase of 32.88%, while its net profit experienced a year-over-year increase of 88.07%.

Score

Industry at a Glance

Previous score
9.35
Change
0

Financials

8.93

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

10.00

Operational Efficiency

10.00

Growth Potential

10.00

Shareholder Returns

7.84

Insulet Corp's Company Valuation

Currency: USD Updated: 2025-10-30

The company’s current valuation score is 3.60, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is 92.76, which is 51271.54% below the recent high of 47652.24 and 65.55% above the recent low of 31.96.

Score

Industry at a Glance

Previous score
3.60
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 36/210
No Data

Earnings Forecast

Currency: USD Updated: 2025-10-30

The company’s current earnings forecast score is 8.54, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Insulet Corp is 365.00, with a high of 400.00 and a low of 300.00.

Score

Industry at a Glance

Previous score
8.54
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 27 analysts
Buy
Current Rating
360.556
Target Price
+14.04%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

110
Total
7
Median
9
Average
Company name
Ratings
Analysts
Insulet Corp
PODD
27
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
31
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
29
1
2
3
...
22

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-30

The company’s current price momentum score is 6.33, which is lower than the Healthcare Equipment & Supplies industry's average of 6.55. Sideways: Currently, the stock price is trading between the resistance level at 329.46 and the support level at 300.23, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.74
Change
-0.41

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.399
Sell
RSI(14)
41.781
Neutral
STOCH(KDJ)(9,3,3)
15.837
Sell
ATR(14)
7.636
High Vlolatility
CCI(14)
-95.281
Neutral
Williams %R
98.106
Oversold
TRIX(12,20)
0.006
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(5)
Neutral(0)
Buy(1)
Indicators
Value
Direction
MA5
319.834
Sell
MA10
322.626
Sell
MA20
318.625
Sell
MA50
326.697
Sell
MA100
313.297
Sell
MA200
295.202
Buy

Institutional Confidence

Currency: USD Updated: 2025-10-30

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.43. The latest institutional shareholding proportion is 102.08%, representing a quarter-over-quarter decrease of 1.34%. The largest institutional shareholder is The Vanguard, holding a total of 8.68M shares, representing 12.33% of shares outstanding, with 2.21% increase in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
The Vanguard Group, Inc.
Star Investors
8.68M
+0.45%
Fidelity Management & Research Company LLC
6.86M
-3.80%
Capital Research Global Investors
4.74M
-22.06%
BlackRock Institutional Trust Company, N.A.
4.35M
-0.31%
State Street Investment Management (US)
3.06M
+1.08%
Baillie Gifford & Co.
Star Investors
2.14M
-5.14%
Geode Capital Management, L.L.C.
1.93M
+3.12%
ClearBridge Investments, LLC
1.54M
+3.83%
American Century Investment Management, Inc.
1.31M
+13.63%
Fidelity International
1.13M
-12.09%
1
2

Risk Assessment

Currency: USD Updated: 2025-10-30

The company’s current risk assessment score is 8.05, which is higher than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 1.39. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
8.05
Change
0
Beta vs S&P 500 index
1.39
VaR
+4.12%
240-Day Maximum Drawdown
+17.77%
240-Day Volatility
+39.26%

Return

Best Daily Return
60 days
+9.47%
120 days
+20.88%
5 years
+22.58%
Worst Daily Return
60 days
-4.31%
120 days
-4.52%
5 years
-9.40%
Sharpe Ratio
60 days
+1.56
120 days
+1.19
5 years
+0.24

Risk Assessment

Maximum Drawdown
240 days
+17.77%
3 years
+61.31%
5 years
+61.31%
Return-to-Drawdown Ratio
240 days
+0.90
3 years
+0.02
5 years
+0.02
Skewness
240 days
+3.10
3 years
+1.16
5 years
+1.16

Volatility

Realised Volatility
240 days
+39.26%
5 years
+45.37%
Standardised True Range
240 days
+2.73%
5 years
+2.92%
Downside Risk-Adjusted Return
120 days
+298.22%
240 days
+298.22%
Maximum Daily Upside Volatility
60 days
+34.88%
Maximum Daily Downside Volatility
60 days
+25.15%

Liquidity

Average Turnover Rate
60 days
+0.99%
120 days
+1.12%
5 years
--
Turnover Deviation
20 days
-15.82%
60 days
-15.48%
120 days
-4.24%

Peer Comparison

Healthcare Equipment & Supplies
Insulet Corp
Insulet Corp
PODD
7.66 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
Artivion Inc
AORT
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Hologic Inc
Hologic Inc
HOLX
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
Lantheus Holdings Inc
LNTH
8.36 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
Edwards Lifesciences Corp
EW
8.32 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI